Logo Logo
Hilfe
Hilfe
Switch Language to English

Greil, Waldemar; Zhang, Xueqiong; Stassen, Hans; Grohmann, Renate; Bridler, Rene; Hasler, Gregor; Toto, Sermin; Bleich, Stefan und Kasper, Siegfried (2019): Cutaneous adverse drug reactions to psychotropic drugs and their risk factors - a case-control study. In: European Neuropsychopharmacology, Bd. 29, Nr. 1: S. 111-121

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Cutaneous adverse drug reactions (CADRs) in patients with psychotropic drugs are common. Large studies on the relevant drugs and other risk factors are still scarce. 594 cases of severe CADRs ("cases") were compared with 8085 cases of other adverse drug reactions ("non-cases") documented in a pharmacovigilance program in psychiatry (AMSP) from 1993 to 2014. Logistic regression was carried out to determine risk factors and between-drug differences. CADRs were relatively more prevalent in patients treated with clomipramine, maprotiline, carbamazepine, lamotrigine, acamprosate, clomethiazole and disulfiram as well as with antidepressants and anticonvulsants as drug classes (p < 0.01). For these drugs, significantly more women were found in patients using maprotiline, lamotrigine (not carbamazepine) and in the groups of antidepressants, tricyclics and anticonvulsants (p < 0.01). Women were more vulnerable to CADRs (67% in cases and 56% in non-cases, p < 0.01). The significantly higher rate of CADRs in women was mainly observed under age of 50 years, i.e. during female reproductive years. In a multivariate logistic regression, female sex, the diagnostic group ICD F1 (substance abuse), maprotiline, carbamazepine, lamotrigine and clomethiazole were identified as risk factors of CADRs. The case/non-case approach allowed to identify risk factors based on empirical data rather than experts' evaluations. The new findings of substance abuse and clomethiazole as risk factors for CADRs have to be confirmed in further studies. Since CADRs can be life-threatening, it is important to be aware of risk factors, especially women during their reproductive period and with lamotrigine treatment. (c) 2018 The Authors. Published by Elsevier B.V.

Dokument bearbeiten Dokument bearbeiten